ZURICH/BERLIN, Jan 21 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,015 points on Monday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
A Swiss court is due to deliver a verdict in the case of a former UBS banker who allegedly sold records of German clients to tax authorities in that country in 2012, resulting in charges of spying, breaking Switzerland’s banking secrecy laws and money laundering.
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment, Herceptin.
Chief Executive Ulrich Spiesshofer told Swiss newspaper Neue Zuercher Zeitung the company could make further acquisitions in the fields of industrial automation and robotics.
* Interroll said on Monday orders rose to 532.6 million CHF 2018, a 29.4 percent increase compared with the previous year.
No major economic data scheduled.
Reporting by Zurich newsroom and Berlin Speed Desk